secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2026-06-25T20:26:17+00:00
Accession:  0001193125-26-282855
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies prices $200M public offering of 32.5M shares at $6.00/share
--------------------------------------------------------------------------------

- Offering of 32,500,001 shares at $6.00/share and 833,333 pre-funded warrants at $5.999.
- Net proceeds ~$187.4M; up to ~$215.6M if underwriters exercise 5M over-allotment option.
- Underwriters: Jefferies, Goldman Sachs, Piper Sandler, Cantor; Baird as lead manager.
- Company expects cash runway into second half of 2028.
- Offering expected to close June 26, 2026; dilution to existing shareholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526282855/0001193125-26-282855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526282855/d121397d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-282855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer